TABLE 3

Patient Demographics and Tumor Response Are Assessed by MR Imaging in Previously Treated Liver Lobe 6 Weeks After 90Y Radioembolization

RECIST 1.1
DemographicPR (n = 3)Stable disease (n = 49)PD (n = 6)
Age (y)65.7 ± 1.260.4 ± 11.059.5 ± 11.2
Sex
 Female (n)2 (3.4)19 (32.8)2 (3.4)
 Male (n)1 (1.7)30 (51.7)4 (6.9)
Dose of 99mTc-MAA given (MBq)153.3 ± 7.6152.4 ± 34.1158.0 ± 32.3
Liver-to-lung shunt (%)6.2 ± 4.56.6 ± 3.47.7 ± 3.7
Dose of 90Y given (MBq)1,266.7 ± 208.21,144.6 ± 203.71,000.0 ± 298.3
Low 99mTc-MAA
 Group 105 (8.6)0
 Group 21 (1.7)17 (29.3)2 (3.4)
High 99mTc-MAA
 Group 31 (1.7)20 (34.5)3 (5.2)
 Group 41 (1.7)7 (12.1)1 (1.7)
Catheter position
 Identical3 (5.2)30 (51.7)3 (5.2)
 Different019 (32.8)3 (5.2)
  • Data are mean ± SD or n, with percentages in parentheses. Total number of patients was 58.